Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin – Yahoo Finance

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin Yahoo Finance
Why Novo Jumped — And Took Out Lilly And Viking Stocks Investor’s Business Daily
This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. Barron’s

Brought to you by Google News. Read the rest of the article here.